Other

Ascendis COACH Week 78 Data Shows Durable Growth

August 06, 2026 1 min read 5 views
cybersecurity news newsapi
Ascendis Pharma reported Week 78 results from its Phase 2 COACH trial, showing durable proportional growth with TransCon CNP and hGH combination therapy, plus YUVIWEL uptake updates.

Was this article helpful?

0 found this helpful

Related Articles

curl Patches HTTP/2 Upload Flaw After PoC Demonstrates Client-Side Code Execution

1 min read

Upcoming Speaking Engagements

1 min read

Cyberattack on Connected Fridges in France

1 min read

Ready to protect your organization?

Get started with Phishlens and run your first phishing simulation today.

Schedule a Demo